A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus.

Trial Profile

A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2016

At a glance

  • Drugs Pimodivir (Primary)
  • Indications Influenza A virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Mar 2013 Primary endpoint 'Viral-shedding' has been met, according to a Vertex Pharmaceuticals media release.
    • 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Results are expected before the end of 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top